A detailed history of Prelude Capital Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Prelude Capital Management, LLC holds 38,900 shares of BCRX stock, worth $295,640. This represents 0.02% of its overall portfolio holdings.

Number of Shares
38,900
Previous 38,900 -0.0%
Holding current value
$295,640
Previous $295,000 -0.0%
% of portfolio
0.02%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $249,349 - $338,041
38,900 New
38,900 $295,000
Q1 2020

May 15, 2020

BUY
$1.6 - $4.11 $39,092 - $100,419
24,433 New
24,433 $49,000
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $8,967 - $13,379
-3,587 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $10,438 - $32,821
3,587 New
3,587 $14,000
Q4 2018

Feb 14, 2019

SELL
$6.51 - $9.6 $8,580 - $12,652
-1,318 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $7,275 - $10,530
1,318 New
1,318 $10,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.